Immune Therapeutics, Inc. (IMUN) [Rocket]

Overview

Immune Therapeutics, Inc. (IMUN)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/18/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/14/2023	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
04/20/2023	8-K	Quarterly results
03/31/2023	NT 10-K	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/27/2023	DEF 14C	Form DEF 14C - Other definitive information statements:
03/06/2023	8-K	Submission of Matters to a Vote of Security Holders  Interactive Data
02/22/2023	4	Farmer Glen A (CFO) has filed a Form 4 on Immune Therapeutics, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Revenue growth			-100.0%		-100.0%	-78.6%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	2.9	4.3	0.0
Gross profit	0.0	0.0	0.0	0.1	0.0	-2.9	-4.3	0.0
Gross margin	0.0%			58.0%		-83944.2%	-26625.7%
Selling, general and administrative	0.6	0.8	2.4	3.2	2.8	3.9	2.7	4.1
Research and development	0.2	0.1	0.3	0.1	0.4	0.4	1.0	2.4
EBITA	3.8	-0.9	-2.8	-4.5	-5.9	-14.3	-10.0	-32.5
EBITA margin	1898476.5%			-3930.4%		-412125.0%	-61642.9%
Amortization of intangibles							0.6	2.9
EBIT	3.8	-0.9	-2.8	-4.5	-5.9	-14.3	-10.6	-35.4
EBIT margin	1898476.5%			-3930.4%		-412125.0%	-65299.4%
Pre-tax income	3.6	1.6	-3.4	-8.6	-7.9	-19.8	-16.9	-49.9
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	3.6	1.6	-3.4	-8.6	-7.3	-19.5	-14.2	-48.3
Net margin	1793017.0%			-7599.7%		-563713.6%	-87933.0%

Diluted EPS	$0.38	$0.10	($7.59)	($20.08)	($0.02)	($0.09)	($0.09)	($0.49)
Shares outstanding (diluted)	9.4	16.0	0.4	0.4	320.7	216.7	153.2	98.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.